Orano Med expands its Texas Pb-212 R&D center

June 27, 2025, 12:47PMNuclear News

Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.

To continue reading, log in or create a free account!

Related Articles

ANSTO-designed target increases Mo-99 yield

February 25, 2026, 1:00PMNuclear News

The Australian Nuclear Science and Technology Organization (ANSTO) announced that it has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99, with less...